

University of Groningen

Matters of the heart: genetic and molecular characterisation of cardiomyopathies

Posafalvi, Anna

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version

Publisher's PDF, also known as Version of record

Publication date:

2015

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Posafalvi, A. (2015). Matters of the heart: genetic and molecular characterisation of cardiomyopathies [Groningen]: University of Groningen

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

**Matters of the heart:
genetic and molecular characterisation
of cardiomyopathies**

Pósafalvi Anna

The work described in this thesis was supported by the University Medical Center Groningen, the Jan Kornelis de Cock Foundation, the NutsOhra Foundation and the Netherlands Heart Foundation.

Printing of this thesis was supported by the Graduate School of Medical Sciences and the University Library, University of Groningen, Groningen, the Netherlands.

Copyright: © 2015 by Anna Posafalvi

All rights reserved. No parts of this book may be reproduced, stored in retrieval system, or transmitted in any form or by any means without prior written permission of the author and the publishers holding the copyrights of the published articles.

Cover photography: ©Anna Posafalvi

Design: dreamed of by Anna Posafalvi, dreams made come true by Joanna Smolonska

Layout and printing:  Lovebird Design & Printing Solutions

ISBN:

978-90-367-7767-4 (printed)

978-90-367-7766-7 (electronic)



university of
 groningen

**Matters of the heart:
genetic and molecular characterisation
of cardiomyopathies**

PhD thesis

to obtain the degree of PhD at the
University of Groningen
on the authority of the
Rector Magnificus Prof. E. Sterken
and in accordance with
the decision by the College of Deans.

This thesis will be defended in public on

Monday 20 April 2015 at 16:15 hours

by

Anna Posafalvi

born on 17 June 1986
in Debrecen, Hungary

Supervisor

Prof. RJ Sinke

Co-supervisor

Dr. JDH Jongbloed

Assessment committee

Prof. MH Breuning

Prof. RA de Boer

Prof. RMW Hofstra

Drága Nagypámnak...
To my dearest grandfather...

“Wheresoever you go, go with all your heart.”
(Confucius)

Paranymphs

Ena Sokol

Eva Teuling

TABLE OF CONTENTS

Preface: ...about cardiomyopathies in a nutshell	9
Outline of this thesis	15
Appendix 1	
List of genes	16
Frequently used abbreviations	18
Chapter 1: Introduction	
New clinical molecular diagnostic methods for congenital and inherited heart disease (<i>Expert Opin Med Diagn 2011, review</i>)	23
Chapter 2: Candidate gene screening	
2.1: Mutational characterisation of <i>RBM20</i> in dilated cardiomyopathy and other cardiomyopathy subtypes	53
2.2: Missense variants in the rod domain of plectin increase susceptibility to arrhythmogenic right ventricular cardiomyopathy	79
Chapter 3: Exome sequencing	
3.1: Hunting for novel disease genes in autosomal dominant cardiomyopathies: elucidating a role for the sarcomeric pathway	109
3.2: Homozygous <i>SOD2</i> mutation as a cause of lethal neonatal dilated cardiomyopathy	139
3.3: One family, two cardiomyopathy subtypes, three disease genes: an intriguing case	157
Chapter 4: Targeted sequencing	
4.1: Gene-panel based Next Generation Sequencing (NGS) substantially improves clinical genetic diagnostics in inherited cardiomyopathies	173
4.2: Titin gene mutations are common in families with both peripartum cardiomyopathy and dilated cardiomyopathy (<i>Eur Heart J 2014</i>)	209
Chapter 5: Discussion and future perspectives	233
Summary	251
Appendix 2	
List of authors and affiliations	268
About the author	270
Acknowledgements	272

...about cardiomyopathies in a nutshell

The disease

Cardiomyopathy is an insidious disease of the heart muscle (myocardium) leading to decreased pumping capacity, and resulting in a wide range of symptoms. These range from mild (dizziness, fatigue, chest pain or oedema) to severe (heart failure, arrhythmia, embolism, or even sudden death).




Figure 1. Schematic cross-section of a healthy heart (a) and hearts with DCM (b), HCM (c) and ARVC (d)

In dilated cardiomyopathy (DCM), the left ventricle becomes enlarged with a thin, weakened muscle wall, and is unable to generate enough pumping force during contractions; the myocardium is thickened in hypertrophic cardiomyopathy (HCM); in arrhythmogenic right ventricular cardiomyopathy (ARVC) fibrofatty infiltration of the myocardium leads to arrhythmia.

Figure published by Wilde & Behr, *Nature Reviews Cardiology*, 2013; used with permission. For more information on cardiomyopathy types, see box 1.

Clinical diagnosis and treatment guidelines

When the symptoms of cardiomyopathy appear, the **diagnosis of the disease** is most frequently made by electrocardiogram (ECG), and non-invasive imaging techniques such as an X-ray of the chest, echocardiography (imaging of the heart with ultrasound), or MRI. In addition, patients receive a general medical examination combined with a simple blood test (measuring, for instance, molecular markers of heart failure or kidney function). Less regularly, cardiac catheterization or coronary angiography is used. Both these methods are “minimally invasive”, only a thin tube is inserted in one of the biggest veins of the body and threaded to the heart, instead of an open surgery. These help physicians acquire either a myocardial biopsy for further experimental analysis or enough information to exclude potential blockage (stenosis) of the heart and the coronary blood vessels.

The **therapy** for cardiomyopathy largely depends on the disease type and the severity of the symptoms. Therapy aims at slowing down the progression of the disease or at disease prevention in susceptible individuals through life style changes and medical treatment using different antihypertensive, antiarrhythmic, diuretic or anticoagulant drugs (e.g., ACE inhibitors or calcium antagonists). In serious cases of arrhythmia, the implementation of an ICD (a small, implantable defibrillator) or a pacemaker may be the solution. Heart transplantation is only considered as a last resort in patients with end-stage heart failure.

The genetic causes

Even though there are several environmental factors that may trigger the onset of cardiomyopathy (viral infections, the use of certain drugs, alcoholism, and other cardiovascular conditions, as well as certain systemic disorders), we often see the disease running in families (30-50% of ARVC and DCM cases; see box 1 for definitions). Most of these familial cardiomyopathy cases can be explained by an **autosomal dominant** (AD) inheritance pattern. To date, about 76 genes are known to be involved in different types of cardiomyopathy, which often show considerable genetic overlap (figure 2), and the majority of these 76 genes show AD inheritance. Additionally, a few genes, such as *DMD*, *EMD*, *GLA*, *LAMP2*, or *TAZ*, are involved in the **X-linked** form of the disease. Exceptionally, **autosomal recessive** inheritance is also observed. These patients usually exhibit more severe symptoms, and the disease generally begins in infancy or early childhood (paediatric cardiomyopathies; the genes involved include *ANO5*, *MYL2*, *PKP2*, *TNNI3*).

Although it is also known that abnormalities in **mitochondrial DNA** can contribute to the pathogenesis of different cardiomyopathies (e.g., mutations of *MTTL1*), this has not yet been extensively studied. The possible complex, **oligogenic** or multifactorial causes for cardiomyopathies have also not been investigated in detail, nor have the potential roles of **risk alleles** of lower effect size, **copy number variations** (such as those including the *BAG3* or *PRDM16* genes), or **microRNAs**. To date, a significant proportion of familial cardiomyopathies (about 30-40% of HCM, 40-50% of ARVC, and around 50% of DCM cases; see box 1 for definitions) remain genetically unexplained.




Figure 2. Cardiomyopathy disease genes and the genetic overlap between subtypes of the disease (updated from Jongbloed et al, EOMD 2011)

Not only is there considerable phenotypic overlap between the subtypes of cardiomyopathy, many genes are also involved in multiple forms of the disease. The official full names of the abbreviated genes, according to OMIM, are listed in appendix 1.

Types of cardiomyopathy

There are various forms of cardiomyopathy, each with different underlying causes for the insufficient circulation. The cardiomyopathies investigated in this thesis include:

1. **dilated cardiomyopathy (DCM)**: one or both of the ventricles (in most cases only the left one) become enlarged with a thin, weakened muscle wall unable to generate enough pumping force during contractions (figure 1)
2. **arrhythmogenic right ventricular cardiomyopathy (ARVC)**: the replacement of the degenerating myocardium with scar (fibrofatty) tissue results in disturbed electrical signals and conduction in the heart (arrhythmia)
3. **hypertrophic cardiomyopathy (HCM)**: a thickened myocardium due to abnormal growth and arrangement (hypertrophy and disarray) of muscle fibres results in smaller chamber volume and sometimes blocks the blood flow (obstruction)
4. **restrictive cardiomyopathy (RCM)**: due to their stiffness, the ventricles do not get refilled with enough blood during relaxation, hence the heart cannot supply the organs with sufficient circulation during contraction
5. **left-ventricular non-compaction cardiomyopathy (LVNC)**: the wall of the left ventricle is spongiform, characterized by a meshwork of muscle fibres
6. **peripartum cardiomyopathy (PPCM)**: a special form of dilated cardiomyopathy that becomes manifest towards the end of pregnancy or within a few months following delivery
7. **paediatric cardiomyopathy**: this type of cardiomyopathy becomes manifest in infancy or early childhood, and is usually characterized by more severe symptoms and worse outcomes than when the disease manifests in adulthood (from a structural-functional point of view, most frequently it is DCM>HCM>RCM>ARVC)

Our methods

Candidate gene screening

- **Sanger-sequencing**: This method of DNA-sequencing allows us to detect single nucleotide changes and small indels of DNA fragments with an average size of 400-500 base pairs. It can be used for screening candidate genes in a large cohort of patients, as well as for segregation analysis of a variant within a family, or for confirmation of DNA-variations detected by high-throughput sequencing.

Disease gene mapping

- **haplotype sharing test (HST)**: An ideal, SNP-genotyping-based method for small cardiomyopathy families, who are usually not suitable for classical linkage analysis. With this method, we aim to identify chromosomal regions shared among affected family members, hypothesizing that the highest chance of finding the mutation is in the largest shared region of the family. We use this method as a filtering step in exome sequencing data analysis – if a variant is located in the 2nd largest shared haplotype of 10 cM, it is more likely to be causative than a variant located in the 57th largest shared haplotype of only 0.1 cM.

High-throughput sequencing

- **exome sequencing**: Sequencing all coding parts (exons) of all genes (about 1% of the genome). Though costly and requiring intensive data analysis, this method is suitable for identifying private coding mutations of novel disease genes in families with an unknown genetic cause of cardiomyopathy.
- **gene-panel based (targeted) sequencing**: High-throughput sequencing of a DNA sample previously enriched for the small set of genes we are interested in. Since this method results in very high coverage across the regions of interest and high data quality, it has recently been implemented in routine diagnostics.

The challenges we face

Identifying a novel disease gene carrying the **heterozygous** causal variant (heterozygous because of the dominant inheritance) is usually more challenging than working on a recessive disease, but there are also other complications to be considered in our research.

Cardiomyopathy is, in general, a **late onset disease**. For example, DCM usually begins between 20 and 50 years of age, while most ARVC patients are diagnosed before 40 years of age. Thus, low penetrance of the disease at young age makes it difficult to make the genetic diagnosis in a family as the disease status of young relatives is uncertain (partly due to the variety in the nature and severity of the symptoms). Furthermore, **phenocopies** also occur, with family members having comparable symptoms due to an independent cause (e.g. developing disease on the basis of another, often non-genetic, cardiovascular event: coronary artery disease). In consequence, the medical diagnosis of cardiomyopathy is based on exclusion criteria and performing segregation analysis for a putative pathogenic variant in families without being absolutely sure of the healthy/affected status of the screened individuals can be complicated.

Since cardiomyopathy can be so difficult to diagnose, and because the chances of a successful treatment rapidly decline with time, our aims are (1) to obtain an **early (molecular) diagnosis** of the inherited form of the disease before severe symptoms become manifest, and (2) to enable **preventive treatment** (including life-style changes as well as medical treatment if necessary) of the endangered individuals, combined with regular, thorough cardiological check-ups.

Recommended literature

- website of the National Heart, Lung, and Blood Institute, health topic on cardiomyopathies: <http://www.nhlbi.nih.gov/health/health-topics/topics/cm/>
- website of the Children's Cardiomyopathy Foundation: http://www.childrenscardiomyopathy.org/site/main_brochure.htm
- Herschberger RE, Lindenfeld J, Mestroni L et al: Genetic evaluation of cardiomyopathy – a Heart Failure Society of America guideline. *J Cardiac Fail* 2009;15:83-97
- Wilde AA & Behr ER: Genetic testing for inherited cardiac disease. *Nat Rev Cardiol* 2013;10:571-83
- Teekakirikul P, Kelly MA, Rehm HL et al: Inherited cardiomyopathies – Molecular genetics and clinical genetic testing in the postgenomic era. *J Mol Diagn* 2013;15:158-70
- Jongbloed JD, Pósaľalvi A, Kerstjens-Frederikse WS et al: New clinical molecular diagnostic methods for congenital and inherited heart disease. *Expert Opin Med Diagn* 2011;5:9-24
- Posaľalvi A, Herkert JC, Sinke RJ et al: Clinical utility gene card for: dilated cardiomyopathy (CMD). *Eur J Hum Genet* 2013;21 doi: 10.1038/ejhg.2012.276
- Te Rijdt WP, Jongbloed JD, de Boer RA et al: Clinical utility gene card for: arrhythmogenic right ventricular cardiomyopathy (ARVC). *Eur J Hum Genet* 2014;22. doi: 10.1038/ejhg.2013.124
- Udeoji DU, Philip KJ, Morrissey RP et al: Left ventricular noncompaction cardiomyopathy: updated review. *Ther Adv Cardiovasc Dis* 2013;7:260-73
- Caleshu C, Sakhuja R, Nussbaum RL et al: Furthering the link between the sarcomere and primary cardiomyopathies: restrictive cardiomyopathy associated with multiple mutations in genes previously associated with hypertrophic or dilated cardiomyopathy. *Am J Med Genet A* 2011;155A:2229-35
- Peled Y, Gramlich M, Yoskovitz G et al: Titin mutation in familial restrictive cardiomyopathy. *Int J Cardiol* 2014;171:24-30
- Wooten EC, Hebl VB, Wolf MJ et al: Formin homology 2 domain containing 3 variants associated with hypertrophic cardiomyopathy. *Circ Cardiovasc Genet* 2013;6:10-8
- Chang B, Nishizawa T, Furutani M et al: Identification of a novel TPM1 mutation in a family with left ventricular noncompaction and sudden death. *Mol Genet Metab* 2011;102:200-6
- Luxán G, Casanova JC, Martínez-Poveda B et al: Mutations in the NOTCH pathway regulator MIB1 cause left ventricular noncompaction cardiomyopathy. *Nat Med* 2013;19:193-201
- Purevjav E, Varela J, Morgado M et al: Nebulette mutations are associated with dilated cardiomyopathy and endocardial fibroelastosis. *J Am Coll Cardiol* 2010;56:1493-502
- Arndt AK, Schafer S, Drenckhahn JD et al: Fine mapping of the 1p36 deletion syndrome identifies mutation of PRDM16 as a cause of cardiomyopathy. *Am J Hum Genet* 2013;93:67-77
- Ohno S, Omura M, Kawamura M et al: Exon 3 deletion of RYR2 encoding cardiac ryanodine receptor is associated with left ventricular non-compaction. *Europace* 2014;16:1646-54
- Pinto JR, Yang SW, Hitz MP et al: Fetal cardiac troponin isoforms rescue the increased Ca²⁺ sensitivity produced by a novel double deletion in cardiac troponin T linked to restrictive cardiomyopathy: a clinical, genetic, and functional approach. *J Biol Chem* 2011;286:20901-12
- van Hengel J, Calore M, Bauce B et al: Mutations in the area composita protein α T-catenin are associated with arrhythmogenic right ventricular cardiomyopathy. *Eur Heart J* 2013;34:201-10
- Pruszczyk P, Kostera-Pruszczyk A, Shatunov A et al: Restrictive cardiomyopathy with atrioventricular conduction block resulting from a desmin mutation. *Int J Cardiol* 2007;117:244-53

OUTLINE OF THIS THESIS

The aims of this thesis are (1) to provide a better understanding of the genetic background and the molecular pathomechanism of familial cardiomyopathies, (2) to identify novel disease genes in unsolved families, and (3) to improve the existing methods of molecular diagnostic testing.

Chapter 1 is a detailed introduction to the field of cardiogenetics. This chapter **reviews** congenital and late onset heart diseases (the latter referring to cardiomyopathies and arrhythmia syndromes), categorizes the genes involved in the different types of heritable heart diseases, and thoroughly describes the research methods with special attention paid to their potential future diagnostic applications in cardiovascular diseases.

The subsequent chapters contain experimental data and are subdivided based on the research methods used.

In **chapter 2**, we applied the classical **candidate gene screening** approach Sanger sequencing. We were interested if (and to what extent) the known DCM gene *RBM20* contributes to the genetic background of the disease in Dutch patients (2.1). In addition, we hypothesized that the desmosomal *PLEC* gene may play a role in the development of ARVC. In an attempt to prove this, we studied the clustering of sequence variations in patients compared to that in a healthy control population (2.2).

High-throughput sequencing is a recent technological development that is revolutionizing the science of genetics. We applied two different experimental designs of this method to elucidate genetic causes for cardiomyopathies. In **chapter 3**, we have described families where mutations in known cardiomyopathy genes had been excluded, and we successfully applied **exome sequencing** to identify novel disease genes in both autosomal dominant (3.1) and recessive (3.2) cardiomyopathies, while 3.3 is an interesting case report on a family suffering from both forms of the disease.

In **chapter 4**, we applied targeted enrichment of DNA samples to a set of well-defined candidate disease genes. We address the applicability and the quantitative advantages of **targeted sequencing** in routine diagnostics for a cohort of 252 unselected cardiomyopathy patients in 4.1, while report our findings on targeted sequencing of PPCM/DCM families in 4.2.

The work described in this thesis is then discussed in a broader context, and future perspectives for the use of high-throughput sequencing in research and diagnostic settings, as well as potential research directions in the field of cardiogenetics, are presented in **chapter 5**.

APPENDIX 1

List of cardiomyopathy genes:

(official abbreviations and names of genes included in figure 2 of the preface)

<i>ABCC9</i>	ATP-binding cassette, subfamily C (CFTR/MRP), member 9
<i>ACTC1</i>	actin, alpha, cardiac muscle 1
<i>ACTN2</i>	actinin, alpha 2
<i>ANKRD1</i>	ankyrin repeat domain 1 (cardiac muscle)
<i>ANO5</i>	anoctamin 5
<i>BAG3</i>	BCL2-associated athanogene 3
<i>CALR3</i>	calreticulin 3
<i>CAV3</i>	caveolin 3
<i>CRYAB</i>	crystalline, alpha B
<i>CSRP3</i>	cysteine and glycine-rich protein 3 (cardiac LIM protein)
<i>CTNNA3</i>	catenin (cadherin-associated protein), alpha 3
<i>DES</i>	desmin
<i>DMD</i>	dystrophin
<i>DOLK</i>	dolichol kinase
<i>DSC2</i>	desmocollin 2
<i>DSG2</i>	desmoglein 2
<i>DSP</i>	desmoplakin
<i>DTNA</i>	dystrobrevin, alpha
<i>EMD</i>	emerin
<i>EYA4</i>	EYA transcriptional coactivator and phosphatase 4
<i>FHL1</i>	four and a half LIM domains 1
<i>FHL2</i>	four and a half LIM domains 2
<i>FHOD3</i>	formin homology 2 domain containing 3
<i>FKRP</i>	fukutin related protein
<i>FKTN</i>	fukutin
<i>FXN</i>	frataxin
<i>GATAD1</i>	GATA zinc finger domain containing protein 1
<i>GLA</i>	galactosidase, alpha
<i>ILK</i>	integrin-linked kinase
<i>JPH2</i>	junctionophilin 2
<i>JUP</i>	junction plakoglobin
<i>LAMA4</i>	laminin, alpha 4
<i>LAMP2</i>	lysosomal-associated membrane protein 2
<i>LDB3</i>	LIM domain binding 3
<i>LMNA</i>	lamin A/C
<i>MIB1</i>	mindbomb E3 ubiquitin protein ligase 1
<i>MT-TL1</i>	mitochondrially encoded tRNA leucine 1 (UUA/G)

<i>MYBPC3</i>	myosin-binding protein C, cardiac
<i>MYH6</i>	myosin, heavy chain 6, cardiac muscle, alpha
<i>MYH7</i>	myosin, heavy chain 7, cardiac muscle, beta
<i>MYL2</i>	myosin, light chain 2, regulatory, cardiac, slow
<i>MYL3</i>	myosin, light chain 3, alkali; ventricular, skeletal, slow
<i>MYLK2</i>	myosin light chain kinase 2
<i>MYOZ2</i>	myozenin 2
<i>MYPN</i>	myopalladin
<i>NEBL</i>	nebullette
<i>NEXN</i>	nexilin (F actin binding protein)
<i>NKX2-5</i>	NK2 homeobox 5
mtDNA	mitochondrial DNA
<i>PDLIM3</i>	PDZ and LIM domain 3
<i>PKP2</i>	plakophilin 2
<i>PLN</i>	phospholamban
<i>PRDM16</i>	PR domain containing 16
<i>PRKAG2</i>	protein kinase, AMP-activated, gamma 2 noncatalytic subunit
<i>PSEN1</i>	presenilin 1
<i>PSEN2</i>	presenilin 2
<i>PTPN11</i>	protein tyrosine phosphatase, non-receptor type 11
<i>RAF1</i>	Raf-1 proto-oncogene, serine/threonine kinase
<i>RBM20</i>	RNA binding motif protein 20
<i>RYR2</i>	ryanodine receptor 2 (cardiac)
<i>SCN5A</i>	sodium channel, voltage-gated, type V, alpha subunit
<i>SDHA</i>	succinate dehydrogenase complex, subunit A, flavoprotein (Fp)
<i>SGCD</i>	sarcoglycan, delta (35kDa dystrophin-associated glycoprotein)
<i>TAZ</i>	tafazzin
<i>TBX20</i>	T-box 20
<i>TCAP</i>	titin-cap
<i>TGFB3</i>	transforming growth factor, beta 3
<i>TMEM43</i>	transmembrane protein 43
<i>TMPO</i>	thymopoietin
<i>TNNC1</i>	troponin C type 1 (slow)
<i>TNNI3</i>	troponin I type 3 (cardiac)
<i>TNNT2</i>	troponin T type 2 (cardiac)
<i>TPM1</i>	tropomyosin 1 (alpha)
<i>TTN</i>	titin
<i>TTR</i>	transthyretin
<i>TXNRD2</i>	thioredoxin reductase 2
<i>VCL</i>	vinculin

APPENDIX 1

Frequently used abbreviations:

ACE	angiotensin convertase enzyme
AD	autosomal dominant inheritance pattern
AGVGD	align Grantham variation Grantham distance (pathogenicity prediction software for missense variants)
AR	autosomal recessive
ARVC	arrhythmogenic right ventricular cardiomyopathy
bp	base pair
CGH	comparative genomic hybridization
CHD	congenital heart disorders
cM	centimorgan
CNV	copy number variation
DCM	dilated cardiomyopathy
dbSNP	NCBI's SNP database
DMEM	Dulbecco's Modified Eagle Medium
DNA	deoxyribonucleic acid
EBS	epidermolysis bullosa simplex
ECG	electrocardiogram
ES	exome sequencing
ESP	exome sequencing project (variant database of the NHLBI)
<i>E. coli</i>	Escherichia coli
FBS	fetal bovine serum
GERP	genomic evolutionary rate profiling (a score indicating the evolutionary conservation of a nucleotide)
GoNL	Genome of the Netherlands (database of the genomes of 500 individuals, used as a frequency database of "the Dutch wild type")
GWAS	genome-wide association study
HCM	hypertrophic cardiomyopathy
HEK	human embryonic kidney 293T cells
HF	heart failure
HiSeq	Illumina's Next Generation Sequencer system
<i>HLA</i>	major histocompatibility complex genes
HST	haplotype-sharing test
H ₂ O	hydrogen oxide (water)
H ₂ O ₂	hydrogen peroxide
ICD	implantable cardioverter-defibrillator
<i>LDB3</i>	LIM domain binding 3 gene
LSH	longest shared haplotype

LVNC	left ventricular non-compaction cardiomyopathy
MD	muscular dystrophy
MiSeq	Illumina's "personal sequencer", the "little sister" of the HiSeq system in benchtop size, with faster workflow, allowing the assembly of small genomes or target regions
MRI	magnetic resonance imaging
mRNA	messenger RNA
NCBI	National Center for Biotechnology Information
NGS	next generation sequencing
NHLBI	National Heart Lung and Blood Institute, a division of National Institutes of Health in the USA
OMIM	"Online Mendelian Inheritance in Man" – a comprehensive database of human genes and genetic phenotypes authored and edited by the Johns Hopkins University
PBS	phosphate buffered saline
PCR	polymerase chain reaction
<i>PLEC</i>	plectin
PolyPhen	Polymorphism phenotype (pathogenicity prediction software for missense variants)
PPCM	peripartum cardiomyopathy
<i>RBM20</i>	RNA binding motif protein 20
RCM	restrictive cardiomyopathy
ROS	reactive oxygen species
RNA	ribonucleic acid
RT	reverse transcription
SCD	sudden cardiac death
SIFT	sorting intolerant from tolerant (pathogenicity prediction software for missense variants)
SNP	single nucleotide polymorphism
<i>SOD2</i>	superoxide dismutase 2
TFC	task force criteria (diagnostic criteria of ARVC)
tRNA	transfer RNA
<i>TTN</i>	titin, the longest gene of the human genome
VOUS	variant of unknown significance
VUS	variant of unknown significance
1000G	1000 Genomes catalog of human genetic variation

